FindTrial
Sign In

Investigating the effect of Ginko biloba on attention deficit hyperactivity disorder symptoms

Investigating the effect of Ginko biloba on attention deficit hyperactivity disorder (ADHD) symptoms in children aged 5 to 15 years

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151123025202N31
Enrollment
30
Registered
2023-10-08
Start date
2023-10-23
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder. Attention-deficit hyperactivity disorders

Interventions

Intervention 1: Intervention group: Intervention group: In addition to the usual treatment and care, this group will receive 3 grams of ginkgo biloba medicine daily for one month. Intervention 2: Cont

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 15 Years

Inclusion criteria

Inclusion criteria: Age 5 to 15 years Normal IQ

Exclusion criteria

Exclusion criteria: patients with neurological or organic disorder Patients on a special diet

Design outcomes

Primary

MeasureTime frame
The outcome of the study includes changes in symptoms of ADHD including sleep quality, nutrition quality, growth rate, academic performance, cognitive status. Timepoint: Before treatment and one month after treatment. Method of measurement: Variables with the 26-question questionnaire of Connors, which contains questions about sleep quality, nutrition quality, growth rate, academic performance, and cognitive status.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Moradi

Hamedan University of Medical Sciences

a.moradi@umsha.ac.ir+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026